Discontinuation and Long-term Follow-up
PD
Sixteen (26.2%) patients discontinued study treatment before completion of the 24-week period: 3 patients discontinued due to AEs, 10 patients discontinued due to PD, 2 patients withdrew consent, and 1 patient discontinued early to have surgery (In the long-term follow-up phase, 4/30 (13.3%) patients with pCR, 10/16 (62.5%) patients with pathologic partial response (pPR), and 2/2 (100%) patients with no response in the ITT population received a combination of adjuvant cyclophosphamide, doxorubicin, platinum, or taxane-based therapy. In addition, of the 10/16 patients with pPR who received adjuvant therapy, 2 patients received capecitabine and 1 patient each received fluorouracil and zoledronic acid.Of the 10 patients who experienced PD, 5 patients received additional neoadjuvant chemotherapy within 1-8 days from the date of PD. Of the 5 patients who received neoadjuvant chemotherapy, all received platinum therapy, 4 patients received paclitaxel, and 4 patients received cyclophosphamide and doxorubicin. Among the 4 patients with PD who received adjuvant chemotherapy following surgery, patients received taxane, cyclophosphamide, pertuzumab, ­trastuzumab, atezolizumab, antimetabolite, and/or platinum therapy. One patient received both additional neoadjuvant and adjuvant chemotherapy.